Federal Register / Vol. 83, No. 159 / Thursday, August 16, 2018 / Notices 40775 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Services is hereby giving notice that the 

Advisory Committee on Blood and 

Tissue Safety and Availability 

(ACBTSA) will hold a meeting. The 

meeting will be open to the public. 

DATES: The meeting will take place on 

Thursday, September 13, 2018, from 

8:00 a.m.–5:00 p.m. ET. 

ADDRESSES: Crystal City Marriott at 

Reagan National Airport, 1999 Jefferson 

Davis Highway, Arlington, VA 22202. 

FOR FURTHER INFORMATION CONTACT: Mr. 

James Berger, Designated Federal Officer 

for the ACBTSA, Senior Advisor for 

Blood and Tissue Policy, Office of the 

Assistant Secretary for Health, 

Department of Health and Human 

Services, Mary E. Switzer Building, 330 

C Street SW, Suite L100, Washington, 

DC 20024. Phone: (202) 795–7697; Fax: 

(202) 691–2102; Email: ACBTSA@

hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

ACBTSA provides advice to the 

Secretary through the Assistant 

Secretary for Health. The Committee 

advises on a range of policy issues to 

include: (1) Identification of public 

health issues through surveillance of 

blood and tissue safety issues with 

national biovigilance data tools; (2) 

identification of public health issues 

that affect availability of blood, blood 

products, and tissues; (3) broad public 

health, ethical, and legal issues related 

to the safety of blood, blood products, 

and tissues; (4) the impact of various 

economic factors (e.g., product cost and 

supply) on safety and availability of 

blood, blood products, and tissues; (5) 

risk communications related to blood 

transfusion and tissue transplantation; 

and (6) identification of infectious 

disease transmission issues for blood, 

organs, blood stem cells and tissues. 

The Committee has met regularly since 

its establishment in 1997. The 

Committee will meet on September 13, 

2018 to receive presentations on 

material pertinent to exploring the topic 

of ‘‘Defining a tolerable risk for 

infectious diseases from a patient’s 

perspective.’’ Historical aspects of 

combating infectious disease risks in the 

blood supply, ongoing national and 

global efforts towards mitigating those 

risks, and emerging considerations shall 

be presented to the Committee. The full 

Committee will receive an interim 

report from the ACBTSA Blood 

Sustainability subcommittee and 

additional topics that are pertinent to 

the mission of the Committee may be 

added to the agenda. 

The public will have an opportunity 

to present their views to the Committee 

during public comment session 

scheduled for the meeting. Comments 

will be limited to five minutes per 

speaker and must be pertinent to the 

discussion. Pre-registration is required 

for participation in the public comment 

session. Any member of the public who 

would like to participate in this session 

is required to submit their name, email, 

and comment summary prior to close of 

business on September 7, 2018. If it is 

not possible to provide 30 copies of the 

material to be distributed at the meeting, 

then individuals are requested to 

provide a minimum of one (1) copy of 

the document(s) to be distributed prior 

to the close of business on September 7, 

2018. It is also requested that any 

member of the public who wishes to 

provide comments to the Committee 

utilizing electronic data projection 

submit the necessary material to the 

Designated Federal Officer prior to the 

close of business on September 7, 2018. 

Dated: August 9, 2018. 

James J. Berger, 

Senior Advisor for Blood and Tissue Policy. 

[FR Doc. 2018–17617 Filed 8–15–18; 8:45 am] 

BILLING CODE 4150–41–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the National Vaccine 

Advisory Committee 

AGENCY: National Vaccine Program 

Office, Office of the Assistant Secretary 

for Health, Office of the Secretary, 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services is hereby giving notice that a 

meeting is scheduled to be held for the 

National Vaccine Advisory Committee 

(NVAC). The meeting will be open to 

the public; public comment sessions 

will be held during the meeting. 

DATES: The meeting will be held on 

September 12 and 13, 2018. The 

meeting times and agenda will be 

posted on the NVAC website at http:// 

www.hhs.gov/nvpo/nvac/meetings/ 

index.html as soon as they become 

available. 

ADDRESSES: U.S. Department of Health 

and Human Services, Hubert H. 

Humphrey Building, Room 800, 200 

Independence Avenue SW, Washington, 

DC 20201. The meeting can also be 

accessed through a live webcast on both 

days of the meeting. For more 

information, visit http://www.hhs.gov/ 

nvpo/nvac/meetings/index.html. 

Pre-registration is required for 

members of the public who wish to 

attend the meeting and who wish to 

participate in a public comment session. 

Individuals who wish to attend the 

meeting and/or participate in a public 

comment session should register at 

http://www.hhs.gov/nvpo/nvac/ 

meetings/index.html. Participants may 

also register by emailing nvpo@hhs.gov 

or by calling (202) 690–5566 and 

providing their name, organization, and 

email address. 

FOR FURTHER INFORMATION CONTACT: Ann 

Aikin, Acting Designated Federal 

Officer, National Vaccine Program 

Office, U.S. Department of Health and 

Human Services, Room 715H, Hubert H. 

Humphrey Building, 200 Independence 

Avenue SW, Washington, DC 20201. 

Phone: (202) 690–5566; email: nvac@

hhs.gov. 

SUPPLEMENTARY INFORMATION: Pursuant 

to Section 2101 of the Public Health 

Service Act (42 U.S.C. 300aa–1), the 

Secretary of Health and Human Services 

was mandated to establish the National 

Vaccine Program to achieve optimal 

prevention of human infectious diseases 

through immunization and to achieve 

optimal prevention against adverse 

reactions to vaccines. The NVAC was 

established to provide advice and make 

recommendations to the Director of the 

National Vaccine Program on matters 

related to the Program’s responsibilities. 

The Assistant Secretary for Health 

serves as Director of the National 

Vaccine Program. During the September 

2018 NVAC meeting, sessions will 

consist of presentations on valuing 

vaccines, including presentations on the 

role of vaccines in combatting antibiotic 

resistance; vaccine innovation, 

including presentations on financing, 

new technologies, and development of 

new vaccines; lessons from the field, 

with focus on Ebola and the new 

Shingles vaccine; and a session on HPV 

vaccination for cancer prevention. 

Please note that agenda items will be 

related to the charge of the Committee 

and are subject to change as priorities 

dictate. Information on the final meeting 

agenda will be posted prior to the 

meeting on the NVAC website: http://

www.hhs.gov/nvpo/nvac/index.html. 

Public attendance at the meeting is 

limited to the available space. 

Individuals who plan to attend in 

person and need special assistance, 

such as sign language interpretation or 

other reasonable accommodations, 


sradovich on DSK3GMQ082PROD with NOTICES
40776 Federal Register / Vol. 83, No. 159 / Thursday, August 16, 2018 / Notices 

should notify the National Vaccine 

Program Office at the address/phone 

number listed above at least one week 

prior to the meeting. For those unable to 

attend in person, a live webcast will be 

available. More information on 

registration and accessing the webcast 

can be found at http://www.hhs.gov/ 

nvpo/nvac/meetings/index.html. 

Members of the public will have the 

opportunity to provide comments at the 

NVAC meeting during the public 

comment periods designated on the 

agenda. Public comments made during 

the meeting will be limited to three 

minutes per person to ensure time is 

allotted for all those wishing to speak. 

Individuals are also welcome to submit 

their written comments. Written 

comments should not exceed three 

pages in length. Individuals submitting 

written comments should email their 

comments to the National Vaccine 

Program Office (nvpo@hhs.gov) at least 

five business days prior to the meeting. 

Dated: July 31, 2018. 

Roula K. Sweis, 

Chief of Management and Operations, 

National Vaccine Program Office. 

[FR Doc. 2018–17618 Filed 8–15–18; 8:45 am] 

BILLING CODE 4150–44–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Planning Grant (R34). 

Date: September 10, 2018. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5601 

Fishers Lane, Rockville, MD 20892 

(Telephone Conference Call). 

Contact Person: Zhuqing (Charlie) Li, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, Room #3G41B, National Institutes 

of Health/NIAID, 5601 Fishers Lane, 

MSC9823, Bethesda, MD 20892–9823, (240) 

669–5068, zhuqing.li@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: August 10, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–17676 Filed 8–15–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental and 

Craniofacial Research; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory Dental 

and Craniofacial Research Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Dental and Craniofacial Research Council. 

Date: September 13, 2018. 

Open: 8:30 a.m. to 12:30 p.m. 

Agenda: Report to the Director, NIDCR. 

Place: National Institutes of Health 

Building 35, Room 620/630, 35 Convent 

Drive, Bethesda, MD 20892. 

Closed: 1:30 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Building 35, Room 620/630, 35 Convent 

Drive, Bethesda, MD 20892. 

Contact Person: Alicia J. Dombroski, Ph.D., 

Director, Division of Extramural Activities, 

National Institute of Dental & Craniofacial 

Research, National Institutes of Health, 

Bethesda, MD 20892, 301–594–4805, 

adombroski@nidcr.nih.gov. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http://

www.nidcr.nih.gov/about, where an agenda 

and any additional information for the 

meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

Dated: August 10, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–17679 Filed 8–15–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Analytical Services Center for Medications 

Development (8938). 

Date: September 25, 2018. 

Time: 10:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Lyle Furr, Scientific 

Review Officer, Office of Extramural Affairs, 


sradovich on DSK3GMQ082PROD with NOTICES